Boston Scientific’s Precision
This article was originally published in The Gray Sheet
Executive Summary
Firm initiates the 150-patient, 15-site PRISM study Nov. 10 to test the safety and efficacy of its spinal cord stimulation system to treat refractory migraine headaches. Boston Scientific says the stimulator could benefit the 2.8 mil. patients in the U.S. who do not respond to traditional migraine therapy...